Pierre Caloz Biography and Net Worth

COO of uniQure

Pierre Caloz served as the SVP, GM-European Union & Asia Pacific Operations at CSL Behring NV. He then worked as the Chief Operating Officer at uniQure NV from 2021 to 2024. Mr. Caloz completed his undergraduate degree at the University of Geneva in 1996.

He obtained a graduate degree from the Swiss Federal Institute of Technology in 1997. In 2010, he earned an MBA from Ashridge Business School.

What is Pierre Caloz's net worth?: The estimated net worth of Pierre Caloz is at least $1.87 million as of February 26th, 2024. Caloz owns 85,643 shares of uniQure stock worth more than $1,870,957 as of December 4th. This net worth evaluation does not reflect any other assets that Caloz may own. Additionally, Caloz receives a salary of $882,590.00 as COO at uniQure. Learn More about Pierre Caloz's net worth.
How old is Pierre Caloz?: Caloz is currently 52 years old. There are 3 older executives and no younger executives at uniQure. The oldest executive at uniQure is Dr. Walid Abi-Saab M.D., Chief Medical Officer, who is 59 years old. Learn More on Pierre Caloz's age.
What is Pierre Caloz's salary?: As the COO of uniQure N.V., Caloz earns $882,590.00 per year. The highest earning executive at uniQure is Mr. Matthew Craig Kapusta, CEO & Executive Director, who commands a salary of $1,020,000.00 per year. Learn More on Pierre Caloz's salary.
How do I contact Pierre Caloz?: The corporate mailing address for Caloz and other uniQure executives is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. uniQure can also be reached via phone at (120) 240-6000 and via email at investors@uniqure. Learn More on Pierre Caloz's contact information.
Has Pierre Caloz been buying or selling shares of uniQure?: Pierre Caloz has not been actively trading shares of uniQure during the past quarter. Most recently, Pierre Caloz sold 9,455 shares of the business's stock in a transaction on Monday, February 26th. The shares were sold at an average price of $6.47, for a transaction totalling $61,173.85. Following the completion of the sale, the chief operating officer now directly owns 85,643 shares of the company's stock, valued at $554,110.21. Learn More on Pierre Caloz's trading history.
Who are uniQure's active insiders?: uniQure's insider roster includes Walid Abi-Saab (Insider), Madhavan Balachandran (Director), Pierre Caloz (COO), Ricardo Dolmetsch (Insider), Robert Gut (Director), Matthew Kapusta (CEO), Jack Kaye (Director), Christian Klemt (CFO), Alexander Kuta, III (VP), David Meek (Director), Leonard Post (Director), and Jeannette Potts (Insider). Learn More on uniQure's active insiders.
Are insiders buying or selling shares of uniQure?: In the last twelve months, insiders at the biotechnology company sold shares 23 times. They sold a total of 432,748 shares worth more than $13,686,033.43. The most recent insider tranaction occured on November, 6th when Director Robert Gut sold 31,434 shares worth more than $856,890.84. Insiders at uniQure own 4.8% of the company. Learn More about insider trades at uniQure.
Information on this page was last updated on 11/6/2025.

Pierre Caloz Insider Trading History at uniQure

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/26/2024	Sell	9,455	$6.47	$61,173.85	85,643
7/10/2023	Sell	15,117	$11.36	$171,729.12	95,098
6/16/2023	Sell	2,920	$18.80	$54,896.00	110,215
3/7/2023	Sell	990	$21.33	$21,116.70	113,135
12/9/2022	Sell	2,941	$22.22	$65,349.02	68,870
6/16/2022	Sell	7,575	$13.21	$100,065.75	64,511

Pierre Caloz Buying and Selling Activity at uniQure

uniQure Company Overview

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Today's Range

Now: $22.74

$21.00

$23.98

50 Day Range

MA: $45.23

$22.74

$70.59

2 Week Range

Now: $22.74

$6.14

$71.50

Volume

9,092,137 shs

Average Volume

2,488,021 shs

Market Capitalization

$1.42 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.59

Pierre Caloz Biography and Net Worth

What is Pierre Caloz's net worth?

How old is Pierre Caloz?

What is Pierre Caloz's salary?

How do I contact Pierre Caloz?

Has Pierre Caloz been buying or selling shares of uniQure?

Who are uniQure's active insiders?

Are insiders buying or selling shares of uniQure?